• <nav id="kqke8"></nav>
  • <input id="kqke8"><u id="kqke8"></u></input>
    <nav id="kqke8"><tt id="kqke8"></tt></nav><nav id="kqke8"></nav>
  • <input id="kqke8"></input>
    <input id="kqke8"><strong id="kqke8"></strong></input>
  • <nav id="kqke8"></nav>

    Overview

    China Pharma Intellectual Property Summit 2016 will be hold in Shanghai by YIP Events on November 17th -18th, devoted to providing a learning and networking platform for those who are engaged in pharma IP protection. We will invite renowned speakers from SIPO, USPTO, EPO, multinational pharma company, local Chinese pharma company, leading law firm to specify the newest pharma patent legislations/policies, share their IP strategies/excellent cases, and discuss hot topics. Below are some information may help to understand this summit better.

    Summit Background:
    IP is playing a very important role in pharmaceutical industry, especially for biopharmaceutical companies. Under the background of fierce competition, patents have undoubtedly been the most effective way to protect their products and kept the advantage of market competition. Patent protection has also become one of the core concerns, not only for multinational pharma companies, but also for local Chinese pharma companies. Biopharmaceutical industry in China is undergoing a very rapid growth, which make pharma IP protection more important and urgent.

    Additionally, pharma patent topics have aroused people’s attention, including: “Patent Cliff”, patent duration under TPP, patent dispute after first biosimilars approved in US, “Patent Dance” in BPCIA, the new Patent Law in China and so on. All of these make this year’s summit more meaningful and time-efficient.

    Why you should not miss this summit?
    1. Mastering pharmaceutical IP protection legislations and policies updates in China, US and Europe
    2. Discussing the hot topics, grasping the future trends
    3. Learning excellent IP cases from leading companies about IP protection, IP defense, IP litigation, IP risks management, IP layout and so on
    4. Building and cementing relationships with your clients/partners face to face

    The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, colleges/institutes, and the meeting scale is expected to 180-200 people. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

    Thanks again for your attention and looking forward to your participation! Sincerely,

    ----Organizing Committee of China Pharma IP Summit 2016



    DAY 1 Morning


    0730 Registration & Morning Coffee


    0845

    Opening Remark

    Day1 Conference Chairperson: Tony Chen, Partner, Jones Day



    0850 China Pharmaceutical Intellectual Property Protection Legislation and Policy Updates
    Qingkui Zhang, Former Director General, Pharmaceutical and Biological Invention Examination Department, SIPO; Chief of the Pharmaceutical Intellectual Property Research Committee of Chinese Pharmaceutical Association


    0930

    Patenting Pharmaceutical and Biotechnological Inventions at the EPO(Including the Latest Developments at the EPO)

    ● Types of patentable inventions in pharma and biotechnology

    ● Exclusions and exceptions to patentability

    ● Recent procedural developments – Early certainty

    ● IP5 developments (International cooperation)

    Dieter Tzschoppe, Director Pharmaceuticals, EPO



    1010

    USPTO Guidelines and Examples Regarding Patent Eligibility in Biotechnology (Section 101)

    Debora Plehn-Dujowich, Chair of the Biotechnology Committee, American Intellectual Property Law Association



    1050 Coffee Break & Refreshments


    1110

    Practical Issues for Global Pharma Companies to Litigate IP Disputes in China

    Fang Qi, Partner, Fangda Partners

    1150 Panel Discussion: The Patent Linkage Promotes Pharmaceutical Innovation in China
    Moderator: Tony Chen, Partner, Jones Day
    Panelists: Randall Rader, Chief Judge of the United States Court of Appeals for the Federal Circuit (Retired in 2014)
    Yongshun Cheng, Director, Beijing Intellectual Property Institute


    1230 Lunch Buffet


    DAY 1 Afternoon


    1400

    Regulatory Data Protection

    ● RDP in Europe, US. and Japan

    ● RDP under TRIPs

    ● RDP in China

    Xu Yang, Senior Patent Attorney, Johnson & Johnson



    1440 Building Effective Patent Defense System to Avoid Patent Barriers
    ● Patent searching and analyzing
    ● Public opinion submitting
    ● Patent invalidation
    Caihui Li, Chief IP Officer, National Engineering Research Center On Antibody Medicine, Sunshine Guojian Pharmaceutical (Shanghai) CO., Ltd



    1520 Coffee Break & Refreshments


    1550 Recent Developments in Pharma Patent Case Laws in Japan
    Takanori ABE, Managing Partner, ABE & PARTNERS


    1630 The Status Quo and Challenges of Pharmaceutical Patent in China
    Wu Li, Senior Consultant, AnJie Law Firm


    1700 Issues to Be Considered When Launching a Generic Drug in Europe
    ● The issue of finding and evaluating relevant third party rights which may cause problems, and steps that can be taken to challenge these rights
    ● The issue of supplementary protection certificates (SPCs) and understand how third-party SPC rights may be challenged
    ● Overview of the Unitary Patent Court and how the recent Brexit vote is likely to affect the implementation of this new system and also how the UK's decision to leave Europe court might affect patentees.
    Jonathan D.M. Atkinson, Partner, HGF Limited


    1730 Panel Discussion: Recent Pharma Patent Litigation Cases Analysis and Its influences
    ● What it means to us that local Chinese pharma company prosecuted multinational pharma company in recent years?
    ● What can we learn from these patent litigation cases?
    Moderator: Heather LIN, Senior Partner and Patent Attorney, NTD Intellectual Property Attorneys
    Panelists: Xu Yang, Senior Patent Attorney, Johnson & Johnson
    Takanori ABE, Managing Partner, ABE & PARTNERS
    Christopher Shaowei, Senior Partner, NTD Patent & Trademark Agency


    1810 Closing Remark


    DAY 2 Morning


    0800 Morning Coffee


    0845

    Opening Remark

    Day2 Conference Chairperson: Weihong Hsing, Partner, Panitch Schwarze Belisario & Nadel LLP



    0850

    Patent Inventiveness Examination of Pharmaceutical and Biotechnology Patent Reexamination Invalid Cases in China
    Renjiu Li, Director of Pharmaceutical and Biological Department, The Patent Reexamination Board of the SIPO



    0930 Sun Tzu--The Art of Global IP War
    ● Developing a global litigation strategy in defending your products.
    ● The challenges to overcome.
    ● The tools you can use from your toolbox.
    Peter L. Dolan, Senior Director - Europe, Asia, Africa and Middle East Patent Support at Merial (a Sanofi Company)


    1010 Coffee Break & Refreshments


    1040

    The Use of Inter Partes Review Petitions in Pharma Patent Litigation

    ● Review of the competing statutes: Hatch-Waxman vs. America Invents Act

    ● Strategies for use of IPR in the pharmaceutical context

    ● Special issues with concurrent ANDA litigation

    Alyson Wooten, Kilpatrick Townsend & Stockton LLP

    Co-Speaker: Alex Trimble, Kilpatrick Townsend & Stockton LLP



    1110

    Biosimilars – Where Are We Now?

    ● What biosimilars have been approved in what regions of the world

    ● Overview of the related IP litigation (and related proceedings such as oppositions and IPRs) in the different

    ● jurisdictions

    ● How a bioisimilar is developed and biosimilar IP protection

    Charles Sholtz, Vice President of Intellectual Property, Coherus Biosciences



    1150

    Panel Discussion: Interpretation Patent Dance of BPCIA and Its Influences on Biosimilars and Innovative Drugs

    Moderator: Weihong Hsing, Partner, Panitch Schwarze Belisario & Nadel LLP

    Panelists: Charles Sholtz, Vice President of Intellectual Property, Coherus Biosciences

    Y. Jenny Chen, Shareholder, Wolf, Greenfield & Sacks, P.C.



    1230 Lunch Buffet


    DAY 2 Afternoon


    1400 What’s the IP Risk and Strategy When Local Chinese Pharmaceutical Company "Going-Out"?
    ● Why local China pharma companies need “going-out”?
    ● Challenges and risks of global IP protection
    ● The importance of communication with lawyers in the target market countries
    ● The best time of IP protections
    Yunli Xue, SVP, Luye Pharma Group Ltd


    1440

    Risk and Reward of IP for Pharma Companies in China

    ● The importance of IP to pharmaceutical industry

    ● The rapid development of China IP environment in recent years

    ● The restrictive IP factors in development of pharmaceutical industry

    ● The opportunity and challenge of multinational pharmaceutical company IP management

    Kent Yang, Senior Patent Attorney, Novartis



    1520 Coffee Break & Refreshments


    1550 The Origins and Operation of the Hatch-Waxman Act and Its Likely Impact in China

    Randall Rader, Former Chief Judge, the United States Court of Appeals for the Federal Circuit (Retired in 2014)



    1630

    Standard Strategy of Pharmaceutical Innovative Technology

    Shengju Deng, Vice President, Beijing Guozhi Patent Warning Consulting Co. Ltd.



    1710 Closing Remark





     

      Media Partner

    天堂AV 国产 亚洲 日韩 制服